Navigation Links
Agendia Receives €1.27 Million in Funding from the EU's Seventh Framework Programme
Date:7/21/2011

IRVINE, California and AMSTERDAM, July 21, 2011 /PRNewswire/ --


 

Agendia, a global innovator in molecular cancer diagnostics, announced today that, together with thought-leading collaborators in clinical centers and translational research groups, it has launched the RATHER (Rational Therapy for Breast Cancer) and COLTHERES (Colon Cancer and Therapeutics) consortiums. The partnerships will collectively receive nearly €12 million in funding from the European Union's 7th Framework Programme over a five-year term. Agendia, in particular, will receive €1.27 million for the development of new molecular diagnostics to help guide individualized treatment of cancer patients.

Both consortiums will be focused on gaining deeper insight into molecular subtypes of breast and colon cancer, and the development of biomarkers for use in predicting patients' individual responses to new targeted drugs. While RATHER seeks to improve treatment for triple negative and lobular breast cancer patients, COLTHERES is focused on response or resistance to targeted therapeutics in colon cancer. Both consortiums consist of clinical partners as well as leading translational research groups with a proven track record in developing companion diagnostics for cancer therapies. The objective of these partnerships is to define and perform biomarker-driven clinical trials to improve cancer therapy outcomes, with Agendia developing reliable and standardized biomarker tests.

Other members of the consortiums include the University College Dublin, the Netherlands Cancer Institute (NKI) Amsterdam, Institute Curie Paris, Malmö University Hospital Lund, Vall d'Hebron Barcelona, University of Cambridge, OncoMark Ltd Dublin, University of Leuven, Niguarda Ca' Granda Hospital Milano, IDIBELL Barcelona, Horizon Discovery UK, University of Liverpool, Swiss Institute of Bioinformatics and the University of Torino School of Medicine.

"We are pleased to participate in these EU funded projects and to work with these outstanding international experts in the fields of functional genomics, pharmacogenetics, bio-informatics and clinical oncology," said Prof. Dr. Rene Bernards, CSO of Agendia. "For Agendia, this is a great opportunity to develop new companion diagnostics together with a large group of scientists and physicians to address urgent clinical needs. The unique consortium structures will allow a rapid translation of results from research and discovery into a clinical setting that benefits patients."

About Agendia:

Agendia is a leading global commercial molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony™ includes MammaPrint®, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint®, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and who can instead be treated with other less arduous and costly methods.

In addition to the Symphony™ suite of tests, Agendia has a rich pipeline of genomic products in development based on its world-class genomic platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Amsterdam, the Netherlands, and Irvine, California, United States. For more information, please visit http://www.agendia.com.

For more information on COLTHERES consortium go to http://www.coltheres.eu/. For more information on the RATHER Project go to http://www.ratherproject.com/.


'/>"/>
SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
2. Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
3. Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
4. FDA Broadens Clearance for Agendias MammaPrint(R)
5. /C O R R E C T I O N -- Agendia B.V./
6. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
7. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
8. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
9. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
10. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
11. Agendia Launches TargetPrint(R) for Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Patients in Alabama ... focused ultrasound (HIFU) therapy no longer have to travel out ... its partnership with Urology Centers of Alabama to ... FDA-cleared procedure for qualifying patients. Alabama ... in the treatment of prostate cancer using many different modalities. ...
(Date:2/5/2016)... 5, 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ... CEO, will be presenting at Source Capital Group,s 2016 Disruptive ... at 2:15 p.m. ET on Wednesday, February 10, ... discussion taking place at 3:15 p.m. ET. http://www.aethlonmedical.com ... hour after the conclusion of the live event. The panel ...
(Date:2/5/2016)... 5, 2016 Dehaier Medical Systems Ltd. ... "Company"), which develops, markets and sells medical devices ... China and international markets, today announced ... to concentrate the Company,s resources to develop its ... and to focus more on its major businesses. ...
Breaking Medicine Technology:
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, ... and organizations with the tools and information to lower the costs, and increase ... the cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
(Date:2/6/2016)... , ... February 06, 2016 ... ... 303-368-6225 , MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE ... perioperative nurses in the world with an estimated 5000 perioperative nurses in ...
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is ... (YUCC) . This event brings together top non-profit leaders, ultimate organizations, and coaches from ... Ultimate”. Valerio Iani, Bay Area Disc Program Director of Youth and Education, describes this ...
(Date:2/6/2016)... Viejo, CA (PRWEB) , ... February 06, 2016 , ... ... quickly and easily add warm color grades to their footage. A LUT is a ... every pixel's color to the corresponding color indicated by the table. By manipulating each ...
Breaking Medicine News(10 mins):